title: 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
authors.affiliation: Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa. mike.sathekge@up.ac.za.
authors.forename: Mike
authors.initials: M
authors.lastname: Sathekge
authors.affiliation: NTP Radioisotopes, The South African Nuclear Energy Corporation, Pelindaba, Pretoria, South Africa.
authors.forename: Otto
authors.initials: O
authors.lastname: Knoesen
authors.affiliation: ITG Isotope Technologies Garching GmbH, Garching bei München, Germany.
authors.forename: Marian
authors.initials: M
authors.lastname: Meckel
authors.affiliation: Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.
authors.forename: Moshe
authors.initials: M
authors.lastname: Modiselle
authors.affiliation: Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.
authors.forename: Mariza
authors.initials: M
authors.lastname: Vorster
authors.affiliation: ITG Isotope Technologies Garching GmbH, Garching bei München, Germany.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Marx
mesh_terms: D000512:Alpha Particles / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology* / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*
chemical_list: C000615137:Bismuth-213; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; C000602389:PSMA-617; D011868:Radioisotopes; D017430:Prostate-Specific Antigen; D001729:Bismuth